|Medicines Management Board Minutes July 2015 (176 KB)||24/09/2015||Download
| ||New Product Request – Levofloxacin Eye Drops - RED Traffic Light.
NHS England Commissioning Policy statement - Hepatitis C- acknowledged .
Dementia Medicines Prescribing Information Sheet – accepted for use in ELHE.
Position Statement for JIA in Adults – accepted for use in ELHE.
Shared Care Guideline – ADHD in children & adolescents up to age of 18 years accept for use for ELHE.
Budesonide - Budenofalk – the Budenofalk brand of budesonide dosing is more flexible than Entocort and it is mor||
|Medicines Management Board Minutes June 2015 (172 KB)||08/09/2015||Download
| ||Eflornithine – red traffic light for licensed indications is acknowledged by dermatology.
Lidocaine patches - within licensed indications for Amber traffic light and would not be continued by GP's for unlicensed indications.
NICE Recommendations: Rifaximin Amber traffic light agreed for ELHE for NICE indication.
Testosterone (Testim) for female sexual dysfunction post oophorectomy or primary ovarian failure - BLACK Traffic Light for ELHE.
The Pharmacological Management of Adults with Chron||
|Medicines Management Board Minutes May 2015 (173 KB)||26/06/2015||Download
| ||Insulin Degludec plus Liraglutide (Xultophy) - Traffic Light: BLACK
Aciferol D3 2000 units/mL Liquid - GREEN Traffic Light
Diclofenac tablets – removed from formulary - BLACK Traffic Light.
ELHE GOOD PRACTICE GUIDANCE WHEN REQUIRED MEDICATION IN CARE HOMES.
ELHE GOOD PRACTICE GUIDANCE CD'S IN CARE HOMES.
|Medicines Management Board Minutes April 2015 (185 KB)||25/06/2015||Download
| ||NEW DRUG REQUEST – SECUKINUMAB - Await NICE guidance.
NEW DRUG REQUEST – PANCREX V POWDER
approved for inclusion in formulary.
Olodaterol in the treatment of COPD - Traffic Light: GREY.
Nalmefene - Traffic Light: RED
Ciprofloxacin eye drops for use in ears - Traffic Light: RED
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrone
NICE (TAG 335). Traffic Light: AMBER.
Empagliflozin in combination therapy for treating type 2 diabetes as dual therap||
|Medicines Mangament Board MInutes March 2015 (177 KB)||25/06/2015||Download
| ||Umeclidinium in COPD -Traffic Light: BLACK
Silk Garments -Traffic Light: BLACK
Lotriderm (Potent steroid and antifungal)-Traffic Light: GREEN
Renacet to replace PhosLo- Traffic Light: AMBER
Vitamin B Compound Strong for Re-Feeding syndrome only - Traffic Light: RED
ELHT Antiplatelet guidance prior to endoscopy approved.
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA14||
|Medicine Management Board Minutes Feb 2015 (134 KB)||27/04/2015||Download
| ||Sugammadex approved for use by Consultant Anaethetist only. Branded Generics for Oxycodone, Fentanyl patches, Isosorbide mononitrate MR, and mebeverine to be included in formulary Vedolizumab for Crohn's Disease – : BLACK Spironolactone for Acne Vulgaris –Traffic Light: RED SSRI's in Premature Ejaculation (PE) – Traffic Light: Amber Dapoxetine for Premature Ejaculation (PE) – is not recommended due to lack of cost and clinical effective evidence, long-term safety concerns and short-acting nature||
|Medicine Management Board Minutes Jan 2015 (147 KB)||27/04/2015||Download
| ||December 2014 meeting postponed so actions carried forward and discussed Jan 2015
Formulary Updates – Fulvestrant (Faslodex) – Consultant has agreed that patients on Faslodex can be referred to clinic for review. Formulary updates – Mirabegron – awaiting response for guidance on choice of treatment for urinary incontinence for use by Primary care clinicians. Nicardipine approved for use on critical care unit. Lacosamide approved for specialist paediatric use. Traffic light: RED ||
|ELHE Medicines Management Board Minutes November 2014 (172 KB)||03/02/2015||Download
| ||Lisdexamphetamine- treatment of ADHD in children and adults only in complex patients who meet two specific criteria- RED Traffic Light.
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma – is recommended as an option by NICE (TAG 321) - RED Traffic Light.
Mexiletine - ventricular tachycardia when other licensed treatments have been unsuccessful - approved for specialist cardiology use RED Traffic Light.
|Medicines Management Board Minutes October 2014 (177 KB)||02/12/2014||Download
| ||Vitamin D Guidleuines - children approved.
Brimonidine gel - symptomatic persistent facial erythema of rosacea - BLACK traffic light .
Opthalmology Macular pathways - approved.
Subcutaneous Tocilzumab - alternative to intravenous tocilizumab providing patient meets the prescribing criteria as set out in NICE technology appraisals for 1st, 2nd & 3rd line use to treat active rheumatoid arthritis and the agreed Lancashire Rheumatology Alliance flex for use as monotherapy - RED traffic light.
|Medicine Management Board Minutes 17th September 2014 (190 KB)||03/11/2014||Download
| ||ELHT Vitamin D Guidelines – Children - approved for use.
Rifaximin added to formulary for hepatic encephalopathy, for consultant gastroenterologist use only and a protocol. Traffic light: RED
Simeprevir to be included in formulary if NICE approve in January.
Pentoxifylline & Vitamin E for osteonecrosis of the jaw approved subject to satisfactory supply arrangements.
Osvaren included in formulary for renal use. Traffic Light: AMBER
Certolizumab - of adults with ankylosing spondylitis in line||
|Medicines Management Board Minutes 16th July 2014 (173 KB)||07/10/2014||Download
| ||Vesomni (solifenacin 6mg/tamsulosin 400mcg MR) - moderate to severe storage symptoms & voiding symptoms associated with benign prostatic hypoplasia - BLACk traffic light.
Lubiprostone - adults with chronic idiopathic constipation - BLACK traffic light.
Certolizumab -treatment of adults with active & progressive psoriatic arthritis in line with NICE TA199 - RED Traffic Light.
Armour Thyroid - unlicensed product - BLACK traffic light.
Canagliflozin - in combination therapy for treatment of typ||
|Medicine Management Board Minutes 21st May 2014 (179 KB)||31/07/2014||Download
| ||NOAC's position Statement - The position statement with a preferred option NOAC will not be pursued and all three will be available for prescribing, with traffic light remaining Amber.
NEW PRODUCT REQUESTS – CARBETOCIN and AZARGA EYE DROPS- deferred